Modality
Nanobody
MOA
FcRni
Target
USP1
Pathway
Fibrosis
GAHeart Failure
Development Pipeline
Preclinical
~Aug 2016
→ ~Nov 2017
Phase 1
Feb 2018
→ Jul 2030
Phase 1Current
NCT08784503
1,379 pts·GA
2018-02→2030-07·Recruiting
NCT03938245
1,085 pts·GA
2025-02→2025-11·Completed
2,464 total pts1 indication
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2025-11-085mo agoPh2 Data· GA
2030-07-114.3y awayPh2 Data· GA
Trial Timeline
2018Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q4
P1/2
Recruit…
P1/2
Complet…
Catalysts
Ph2 Data
2025-11-08 · 5mo ago
GA
Ph2 Data
2030-07-11 · 4.3y away
GA
RecruitingCompleted|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT08784503 | Phase 1/2 | GA | Recruiting | 1379 | VA |
| NCT03938245 | Phase 1/2 | GA | Completed | 1085 | PASI75 |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Suracagene | GSK | Phase 3 | PRMT5 | |
| REG-6699 | Regeneron | Phase 2/3 | TIM-3 | |
| Zanufutibatinib | Intra-Cellular | NDA/BLA | CD38 | |
| Cevinaritide | Praxis Precision | Phase 3 | AuroraA | |
| Fixabrutinib | Verve | Phase 1 | RET | |
| Tezesotorasib | Enliven | Phase 2 | USP1 | |
| ETN-5063 | 89bio | Phase 1/2 | USP1 | |
| PAS-2221 | Passage Bio | Preclinical | GPRC5D | |
| Zoriosocimab | Y-mAbs | Phase 3 | BCL-2 | |
| 450-3790 | Sumitomo Pharma | Preclinical | LAG-3 |